A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

11/05/2022

OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ in London and Boston

Download

To receive OSE Immunotherapeutics’ latest news